Categories: News

A foundation providing care services for the elderly has chosen Aino

A foundation providing care services for the elderly has chosen Aino’s SaaS solution. The agreement covers a total of about 500 employees. Implementation is expected to take place during the third quarter of 2023. 

“We are very pleased with the great trust in Aino and look forward to creating added value and contributing to increased employee sustainability,” says Jyrki Eklund, CEO of Aino Health. 

Aino’s SaaS solution supports managers with internal work ability-related processes and absence management. It also offers reporting and analytics tools to track key metrics related to corporate health management. The goal of the solution is to digitize preventative support processes and increase employee well-being. 


For more information 
Jyrki Eklund
CEO, Aino Health
Phone: +358 40 042 4221 
jyrki.eklund@ainohealth.com  

Certifiedadviser 
Erik Penser Bank 
For more information see: https://investors.ainohealth.com/certified-adviser/ 

About Aino Health (publ) 
Aino Health is the leading provider of Software as a Service solutions within Corporate Health Management. The company’s complete system of SaaS platforms and services reduces sick leave, lowers related costs and improves business results through increased productivity and employee engagement by making health and wellness an integral part of daily work. For more information visit ainohealth.com. 

Staff

Recent Posts

Revitalist Releases Benefits Program Giving Access To All for Ketamine Therapies Changing the Narrative of Mental Health to Risk Mitigation

Vancouver, British Columbia--(Newsfile Corp. - November 25, 2024) - Revitalist Lifestyle and Wellness Ltd. (CSE:…

7 minutes ago

BioHarvest Launches VINIA SuperFood Functional Tea Line

Incremental Product Launch Addresses $3.3 Billion North American Functional Tea Market Opportunity with First SuperFood…

1 hour ago

Neurotech Innovator UNEEG Medical Receives FDA Breakthrough Device Designation Within Monitoring and Diagnostic of Epilepsy

The designation is a result of UNEEG's strong focus on developing novel disease management support…

1 hour ago

Lexaria’s GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled

DehydraTECH-processed tirzepatide from Zepbound® is being tested in an oral dose format KELOWNA, BC /…

1 hour ago

S4 Medical Receives FDA 510(k) Approval for its Redesigned Esophageal Deviation Device and Begins Commercialization

CHAGRIN FALLS, OH / ACCESSWIRE / November 25, 2024 / S4 Medical Corp, an Ohio…

1 hour ago